People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tempo Therapeutics, Inc. | — | Biotechnology | Series B | $20.2M | $134.4M | 2015 |
| Partillion Bioscience Corp | — | Biotechnology | Series A | $4.9M | $53.0M | 2022 |
Dino Di Carlo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dino Di Carlo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL CONLEY | 1 | 17 |
| ERIC MOESSINGER | 1 | 6 |
| Steven Sands | 1 | 2 |
| Steven Richieri | 1 | 2 |
| Biren Mehta | 1 | 2 |
| Joseph De Rutte | 1 | 1 |
| Richard Hancock | 1 | 1 |
| Donald Griffin | 1 | 1 |
| Robin Sitver | 1 | 1 |
| Westbrook Weaver | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.